期刊文献+

系列组合拳,整治抗菌药物 被引量:6

Serial Strict Measures and Policies Proposed by the Ministry of Health to Manage and Regulate me Abuse of Antibacterial Agents
下载PDF
导出
摘要 目的: 综述2011年卫生部采取的系列整治抗菌药物滥用的措施。方法:以2011年的会议为主线,按日期对卫生部出台的系列法规、办法和专项治理措施进行汇总。结果和结论:卫生部以2011年全国医疗工作会议为起始,拟在全国开展抗菌药物应用专项治理活动,活动的治理标准是正在征求意见的《医疗机构抗菌药物管理办法》,必将大大促进抗菌药物的合理使用。 Objective: To summarize the policies and measures regulating the abuse of antibacterial agents during 2011 by the Ministry of Health. Methods: All the regulations and measures were reviewed in order of their executed date. Regulls and e,o^luaion: Starting from the 2011 national medication working conference, Ministry of Health launched a special-purpose regulation against the abuse of antibacterials. The rules of the regulation is based on measures of antibacterial management in medical institution. The regulation will greatly enhance and improve the rational use of antibiotics.
作者 刘治军 胡欣
出处 《药品评价》 CAS 2011年第10期4-6,共3页 Drug Evaluation
关键词 抗菌药物 专项治理 管理办法 合理用药 Antibacterial Special-purpose regulate Management Rational drug utility
  • 相关文献

参考文献5

  • 1刘治军 李玮 张文虎等.2010年中国城镇居民家庭药箱调查活动及主要调查结果报告[J].中国药学杂志,.
  • 2白剑峰.中国平均100个患者1天消耗80.1人份的抗菌药物滥用将被严治[OL].人民网.http://health.people.com.cn/GB/13931466html.2011.02.16/2011-4-20.
  • 3WHO. Global tuberculosis control:surveillance,planning,financing [C]. WHO Report 2007. World Health Organization, Geneva, WHO/ HTM/TB/2007.376.
  • 4郑飞跃,李茜,柳琳,饶跃峰.多重耐药结核杆菌的耐药机制及药物治疗原则[J].药品评价,2010(22):24-27. 被引量:3
  • 5卫生部,国家中医药管理局,总后勤部卫生部.医疗机构药事管理规定[OL].卫生部网.http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3585/201103/51113.htm2011-03-30/2011-5.10.

二级参考文献21

  • 1Cheng J,Kang X,Zhang S,et al.SUMO-specific protease l is essentional for stabilization of HIF-1 alph during hypoxia.CELL,2007,131(3):584.
  • 2World Health Organization.Global tuberculosis control and patient care:a ministerial meeting of high M/XDR-TB burden countries[R].Beijing,China,1-3 April,2009.http://www.who.int/tb_beijingmeeting/en/index.html.
  • 3Sharma SK,Moban A.Multidrug-resistant tuberculosis[J].Indian J Med Res,2004,120:354-376.
  • 4Rastogi N.Emergence of multidrug-resistance tuberculosis fundamental and applied research aspects global issues and current strategies[J].Respir Microbiol,1993,144:103-158.
  • 5Chan RC,Hui M,Chan EW,et al.Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong[J].Antimicrob Chemother,2007,59(5):866-873.
  • 6Brown TJ,Herrera-Leon L,Anthony RM,et al.The use of macroarrays for the identification of MDR Mycobacterium tuberculosis[J].J Microbiol Methods,2006,65:294-300.
  • 7HongLingG,QiHuiS,StevenD,et al.Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterinm tuberculosis from the USA[J].J Med Microbiol,2006,55(11):1527-1531.
  • 8Meier A,Sander P,Schaper KJ,et al.Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant mycobacterium tuberculosis[J].Antimicrob Agents Chemother,1996,40(11):2452-2454.
  • 9Mitnik CD,Shin SS,Seung KJ,et al.Comp rehensive treatment of extensive drug-resistant tuberculosis.N Engl J Med,2008,359(6):563-574.
  • 10Katiyar SK,Bihari S,Prakash S,et al.A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrug-reisistant tuberculosis.Int J Tuberc Long Dis,2008,12:139-145.

共引文献2

同被引文献23

  • 1王江云,陈勇,卢伟,韦传军.原发性肝癌经动脉化疗栓塞预防性应用抗生素前瞻性研究[J].第一军医大学学报,2005,25(6):757-758. 被引量:7
  • 2王艳,王利.加强药品注册现场核查 打击虚假药品研制行为[J].中国药事,2007,21(1):18-18. 被引量:4
  • 3肖秀红,徐凤琴,陈丽容,张丽崧,邵怀好.外科围手术期抗菌药物应用的调查分析[J].中华医院感染学杂志,2007,17(3):320-321. 被引量:85
  • 4卫生部.抗菌药物临床应用指导原则[Z].卫医发[2004]285号,2004.
  • 5卫生部办公厅.关于抗菌药物临床应用管理有关问题的通知[Z].卫办医政发[2009]38号.
  • 6Wang Q,Lan F, Xiao AL.Irrational drug use problems and intervertion research[J]. China J Clic Pharmcol,2003,19(l):75-78.
  • 7Ryan JM, Ryan BM, Smith TP. Antibiotic prophylaxis invascular and interventional radiology[J]. JVIR, 2004, 15(6):547-554.
  • 8ICH.DEVELOPMENT SAFETY UPDATE REPORT E2F Current Step 2 version[OL], http://www.pmda.go.jp/ich/e/Step3_ e2f_08_09_12_e.pdf. 2008-6-5/2011-2-22.
  • 9Ellis F. Unger. Background and Overview of the CIOMS VII Project: The DSUR[OL]. FDA net. http://www.fda.gov/downloads/ AboutFDA/CentersO ffices/CDER/ucm120179.pdf. 2006-6- 19/2011-2-11.
  • 10陈新谦;金有豫;汤光.新编药物学[M]北京:人民卫生出版社,200756.

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部